YS-49 (YS49) is a novel and potent anti-inflammatory agent and activator of PI3K/Akt signaling with the potential to be used for treating vascular diseases such as hypertension and atherosclerosis.

Miltefosine (Impavido; HePC), an alkyl-phosphocholine compound, is a potent, orally- and topically-bioactive, broad spectrum antimicrobial and anti-leishmanial medication that also has potential antineoplastic activity.

Recilisib (ON-01210; ON 01210; ON01210; EX-RAD) is a novel and potent radioprotectant undergoing phase I clinical trials by Onconova Therapeutics for the treatment of acute radiation syndrome.

GSK690693, an aminofurazan derivative, is a novel, potent and ATP-competitive pan-Akt inhibitor targeting Akt1/2/3 with potential anticancer activity.

K-80003 (TX-803; K-80003; TX803; K80003) is a novel and potent inhibitor of Akt activation (tRXRα-dependent) with potential anti-cancer activity.

MK-2206 dihydrochloride (2HCl) is a novel, potent, orally bioavailable and highly selective allosteric inhibitor of the serine/threonine protein kinase Akt1/2/3 with potential anticancer activity.

Akti-1/2 (known also as AKT inhibitor VIII), a quinoxaline-based compound, is a novel, potent, selective, cell-permeable and allosteric inhibitor of Akt1/2 with potential anticancer activity.

A-674563 hcl is a novel,potent and selective Akt1 inhibitor ( Ki =11 nM).

BAY1125976 (BAY-1125976) is a novel, orally bioavailable and selective allosteric inhibitor of Akt1/Akt2 with potential anticancer activity.